RELMADA THERAPEUTICS, INC. - 8-K Summary
Business Context and Reporting Period
Relmada Therapeutics, Inc. (RLMD), a Nevada corporation, filed this Current Report on Form 8-K on August 7, 2025. The filing announces a corporate update and preliminary, unaudited financial results for the second fiscal quarter ended June 30, 2025. The company is listed on The NASDAQ Capital Market.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notice that these results are preliminary and unaudited. Complete unaudited financial statements for the three and six months ended June 30, 2025, and 2024, are scheduled to be included in the upcoming Quarterly Report on Form 10-Q.
Material Changes
No specific material changes in financial condition or operations are detailed in the text of this 8-K. The filing references a press release (Exhibit 99.1) and a corporate presentation (Exhibit 99.2) for further details on the quarter's performance and corporate updates.
Guidance, Outlook, and Management Commentary
Management announced a conference call and audio webcast held on August 7, 2025, at 4:30 PM EDT to discuss the corporate update and financial results. The filing includes a Regulation FD disclosure regarding an updated corporate presentation. No specific forward-looking guidance or risk factors are enumerated in the body of this report.
Investor Verification Checklist
- Review the upcoming Form 10-Q for audited financial statements and detailed metrics for the quarter ended June 30, 2025.
- Examine Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures.
- Consult Exhibit 99.2 (Corporate Presentation) for strategic updates and pipeline progress.
- Verify the transcript of the August 7, 2025, conference call for management commentary on the results.